Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)
Status: Enrolling
Updated:  11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Olympia, WA
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)
Status: Enrolling
Updated: 11/25/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Olympia, WA
Click here to add this to my saved trials
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)
Status: Enrolling
Updated:  11/25/2015
mi
from
Wien,
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)
Status: Enrolling
Updated: 11/25/2015
mi
from
Wien,
Click here to add this to my saved trials
Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition
Observational Evaluation Using Continuous Glucose Monitoring to Determine Timing and Frequency of Self-Monitored Blood Glucose by Therapy Type in Patients With Type 2 Diabetes (REACT-4 Matrix Definition Study)
Status: Enrolling
Updated:  11/25/2015
International Diabetes Center
mi
from
Minneapolis, MN
Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition
Observational Evaluation Using Continuous Glucose Monitoring to Determine Timing and Frequency of Self-Monitored Blood Glucose by Therapy Type in Patients With Type 2 Diabetes (REACT-4 Matrix Definition Study)
Status: Enrolling
Updated: 11/25/2015
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Honolulu, HI
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Des Moines, IA
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Hyattsville, MD
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Hyattsville, MD
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chattanooga, TN
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
Click here to add this to my saved trials
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated:  11/27/2015
mi
from
Miranda,
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status: Enrolling
Updated: 11/27/2015
mi
from
Miranda,
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Encino, CA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Encino, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fresno, CA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Huntington Beach, CA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Walnut Creek, CA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Aurora, CO
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
DeLand, FL
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
DeLand, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Hollywood, FL
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Hollywood, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Miami, FL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Lawrenceville, GA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Roswell, GA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Roswell, GA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nampa, ID
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nampa, ID
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Crystal Lake, IL
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Crystal Lake, IL
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Des Moines, IA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Baltimore, MD
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
St. Louis, MO
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nashua, NH
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Nashua, NH
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Flemington, NJ
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Flemington, NJ
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Smithtown, NY
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Smithtown, NY
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Staten Island, NY
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Staten Island, NY
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Asheville, NC
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Asheville, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chapel Hill, NC
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greenville, NC
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greenville, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Morehead City, NC
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Morehead City, NC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greer, SC
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Greer, SC
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chattanooga, TN
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Memphis, TN
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, TX
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Austin, TX
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Austin, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Houston, TX
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Round Rock, TX
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Round Rock, TX
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Spokane, WA
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
Novo Nordisk Clinical Trial Call Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated:  11/27/2015
mi
from
Arlon,
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Status: Enrolling
Updated: 11/27/2015
mi
from
Arlon,
Click here to add this to my saved trials
A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers
A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds
Status: Enrolling
Updated:  11/30/2015
Winston - Salem Outpatient Clinic
mi
from
Winston - Salem, NC
A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers
A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds
Status: Enrolling
Updated: 11/30/2015
Winston - Salem Outpatient Clinic
mi
from
Winston - Salem, NC
Click here to add this to my saved trials
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
Status: Enrolling
Updated:  11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
Status: Enrolling
Updated: 11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide
Status: Enrolling
Updated:  11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide
Status: Enrolling
Updated: 11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Training Doctors to Support Patient Self-Care of Depression
Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors
Status: Enrolling
Updated:  11/30/2015
Sutter Health Sacramento
mi
from
Sacramento, CA
Training Doctors to Support Patient Self-Care of Depression
Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors
Status: Enrolling
Updated: 11/30/2015
Sutter Health Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Training Doctors to Support Patient Self-Care of Depression
Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors
Status: Enrolling
Updated:  11/30/2015
University of California at Davis Health System
mi
from
Sacramento, CA
Training Doctors to Support Patient Self-Care of Depression
Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors
Status: Enrolling
Updated: 11/30/2015
University of California at Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Impact of Periodontal Disease on Outcomes in Diabetes
Impact of Periodontal Disease on Outcomes in Diabetes
Status: Enrolling
Updated:  11/30/2015
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Impact of Periodontal Disease on Outcomes in Diabetes
Impact of Periodontal Disease on Outcomes in Diabetes
Status: Enrolling
Updated: 11/30/2015
University of Nevada School of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials